NCT01228383View on ClinicalTrials.gov

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Rabies
Interventions
BIOLOGICAL

Rabies virus-specific monoclonal antibodies

CL184 20 IU/kg intramuscularly on Day 0.

BIOLOGICAL

human polyclonal rabies immune globulin (HRIG)

HRIG 20 IU/kg intramuscularly on Day 0.

BIOLOGICAL

Placebo

Placebo intramuscularly on Day 0.

BIOLOGICAL

Human diploid cell vaccine (HDCV)

Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.

BIOLOGICAL

Purified verocell rabies vaccine (PVRV)

Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.

Trial Locations (1)

560 052

Lotus House, Vasanth Nagar, Bangalore

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01228383 - Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults | Biotech Hunter | Biotech Hunter